Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

	Lugar i iiriq							101114			
CARACO PHA Form 4 July 24, 2007	ARMACEUTI	CAL LAB	ORAT	ORIES L7	ΓD						
FORM	4		~ ~ ~ ~						PPROVAL		
	UNITED	STATES		RITIES A shington			COMMISSION	N OMB Number:	3235-0287		
Check this l if no longer subject to Section 16. Form 4 or Form 5 obligations may continu	IENT OF suant to S a) of the F	ection 1 Public U	SECUE 16(a) of th Itility Hol	Estimated burden hou response	urs per						
See Instruct 1(b).	tion	30(n) (of the fi	nvestment	Compan	y Act of 1	940				
(Print or Type Res	sponses)										
1. Name and Address of Reporting Person <u>*</u> Crissman John D			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
		CARACO PHARMACEUTICAL LABORATORIES LTD [CPD]				(Check all applicable)					
(Last) (First) (Middle) 540 E. CANFIELD			3. Date of Earliest Transaction (Month/Day/Year) 07/20/2007			X_ Director 10% Owner Officer (give title Other (specify below) below)					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
DETROIT, M	I 48201						Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed o	of, or Beneficia	lly Owned		
	Transaction Date Ionth/Day/Year)	Execution I any	Date, if	Code (Instr. 8)	4. Securiti nAcquired (Disposed o (Instr. 3, 4) Amount	(A) or of (D) and 5) (A) or	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Dominder: Dec	t on o cont- 1'	for or -h - 1	on of				an in dina atl-				
Keminder: Kepor	t on a separate line	ior each cla	iss of sec	urities bene:	Persor inform require	ns who restation cont ed to resp ys a curre	or indirectly. spond to the colle tained in this form ond unless the for ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	nof Derivative	Expiration Date	Underlying Securities	Der
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

Edgar Filing: CARACO PHARMACEUTICAL LABORATORIES LTD - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					(
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Director Stock Option (right to buy)	\$ 16.04	07/20/2007		A		1,500		<u>(1)</u>	07/20/2013	Common Stock	1,500	

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Crissman John D 540 E. CANFIELD DETROIT, MI 48201	Х							
Signatures								
Fred B. Green as attorney-in-fact	07	7/24/2007						
**Signature of Reporting Person		Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The options are exercisable as follows: one-third on 07/20/2008, one-third on 07/20/2009 and one-third on 07/20/2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(In